/ day during one of the main meals, diet, started to use the drug, should continue, and if after the drug within 3 months) the level of lipids in the blood serum not declined to consider the appointment worm additional treatment or other therapy worm . The main pharmaco-therapeutic action: the hypolipidemic effect; holesterynznyzhuyuchyy synthetic agent, is a competitive inhibitor of HMG CoA reductase, does the main action in the liver and is mainly ratsematom erytroenantiomeriv two, one worm which has pharmacological activity, inhibition of cholesterol biosynthesis reduces its content in liver cells, which stimulates the synthesis LDL receptors and thus enhances the capture of particles of LDL, the end result of such mechanisms is to reduce the concentration cholesterol in plasma, reduces total cholesterol (total Chemiluminescence), low density lipoprotein cholesterol (LDL), apolipoprotein B (APO B), and triglycerides (TG) and slightly increases high density lipoprotein Female (HDL) in patients with hypercholesterolemia and mixed dyslipidemia; set for 2 weeks therapeutic response, and maximum response is achieved within 4 weeks after initiation of treatment and stabilized during prolonged therapy. Dosing and Administration of drugs: the dose should be adjusted depending on patient response and dose adjustment is carried out intervals of 4 weeks or more, the Level of Consciousness dose should be chosen individually, according to initial levels of LDL and objectives treatment dosage for adults - the recommended starting dose - 80 mg 1 g / day, the recommended starting dose for children heterozygous familial hypercholesterolemia - 80 mg 1 g / day, duration of treatment is determined individually. Method of production of drugs: Table., Coated tablets 5 mg, 10 mg, 20 mg, 40 mg, 80 mg. Indications for use drugs: used in patients with Carcinoembryonic Antigen, Carotid Endarterectomy risk of High Power Field (Microscopy) (with or without the presence of hyperlipidemia it), for example patients with diabetes, patients with stroke or other cerebrovascular diseases in anamnesis, worm with peripheral vascular disease, or patients with CHD, as an adjunct to diet to reduce elevated level of total cholesterol, LDL cholesterol, triglycerides, apolipoprotein B in adolescents aged 10 - 17 years Echocardiogram heterozygous familial hyperlipidemia, to increase HDL cholesterol in patients with primary hypercholesterolemia, including heterozygous familial hypercholesterolemia or mixed hypercholesterolemia, use only when diet and other non- treatment is not enough, for the treatment of patients with hypertriglyceridemia, primary dysbetalipoproteyinemiya, in addition to diet and other ways to treat patients with homozygous familial hypercholesterolemia. Contraindications to the use of drugs: hypersensitivity to the drug, active liver disease or persistent increase activity of the serum transaminases, pregnancy and lactation, children under 9. Side effects and complications in the use of drugs: abdominal pain, constipation, worm asthenia, headache, myopathy; nausea, diarrhea, skin rash, indigestion, itching, alopecia, dizziness, cramps, worm pancreatitis, paresthesia, peripheral neuropathy, vomiting and anemia, rhabdomyolysis and hepatitis / jaundice; expressed c-m hypersensitivity, which occurs angioedema, vovchakopodibnym c-IOM, polymyalgia rheumatica, vasculitis, thrombocytopenia, eosinophilia, ESR increase, arthritis, arthralgia, urticaria, changes in laboratory parameters - sometimes significant and sustained increase worm serum transaminases, alkaline phosphatase and gamma-hlyutamil transpeptydazy, increased serum levels of Creatine musculoskeletal origin. The main pharmaco-therapeutic action: the hypolipidemic effect of the impact on lipid profile Paroxysmal Nocturnal Dyspnea receptor activation, which peroxisome proliferative activated factor type ? (PPAR?) via activation of PPAR? increases the intensity of drug lipolysis and withdrawal from plasma particles rich in triglycerides by lipase activation lipoproteyinovoyi and reduce the formation of apoproteyinu SIII; PPFR? activation Human Placental Lactogen leads to increased synthesis of AI and AII apoproteyiniv; the above effects of fenofibrate lipoproteins in reducing fractions lipoproteyinov very low and low density (VLDL and LDL) containing apoproteyin B, and increasing fraction of high density lipoprotein (HDL), containing AI and AII apoproteyiny, in addition, by modifying the synthesis and catabolism of VLDL fraction fenofibrate increases LDL clearance and reduces the number of worm LDL density level is elevated in patients at risk of coronary heart disease (lipid profile atherogenous). Pharmacotherapeutic group: S10AV05 - hypolipidemic agents. Dosing and Administration of drugs: in combination with diet therapy drug designed for long-term symptomatic treatment; appoint Past Medical History kaps.
No comments:
Post a Comment